Navigation Links
Molecular imaging enlists prostate enzyme to detect metastases
Date:6/11/2013

Vancouver, British Columbia No matter where they have hidden, metastatic prostate cancer cells still express some of the same signaling as normal prostate cells; in some cases even more so, as with the PSMA enzyme. Harnessing this enzyme could mean the beginning of a new platform for prostate cancer detection, staging, treatment and post-treatment monitoring, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

"There are currently no ideal imaging techniques in clinical practice that are specific to prostate cancer," said Shankar Vallabhajosula, PhD, a professor of radiochemistry from the department of radiology at Weill Cornell Medical College in New York, N.Y. "We regularly use bone scans to image metastatic prostate cancer, but bone scans are not specific for these tumors. This study focuses on a novel imaging agent that binds to PSMA, an enzyme expressed by prostate epithelial cells. We don't really know what its role is in prostate cancer, but imaging agents using either anti-PSMA antibodies or small molecules that specifically bind to the enzymatic site of PSMA are capable of detecting both primary prostate cancer cells and secondary metastases in other organs. This development could lead to highly specific prostate cancer imaging and potentially optimal care for patients."

In two preliminary phase I studies involving PSMA, also known as glutamate carboxypeptidase II(GCPII) or NAAG peptidase,researchers evaluated a novel imaging agent comprising a small molecule of amino acids, called MIP-1404 (based on glutamate-urea-glutamate pharmacophore) radiolabeled with technetium-99m (Tc-99m), a radioactive atom that can be detected by single photon emission computed tomography (SPECT) that provides functional imaging of prostate cancer. Tc-99m MIP-1404 SPECT imaging produces a scan or a map of where this novel agent is bound to PSMA enzyme in metastatic prostate tumors throughout the body. Tc-99m MIP-1404 represents a much more commercially and clinically viable agent because it is easy to manufacture and has a faster rate of distribution throughout the body and clearance from the body, unlike imaging agents based on anti-PSMA monoclonal antibodies that were cumbersome and require long wait times to obtain images.

Results of the study revealed that Tc-99m MIP-1404 was well distributed and ready for imaging as soon as one hour after injection for localization of cancer lesions in bone and lymph nodes. In a majority of cases, Tc-99m MIP-1404 pointed out more lesions than standard bone imaging.

"This agent could one day be a molecular imaging biomarker not just for screening patients with prostate cancer and metastases but also for monitoring their response to subsequent treatment," said Vallabhajosula. "In time, it could also be formulated as a therapeutic radioactive drug."

According to 2013 data from the American Cancer Society, approximately 238,600 new prostate cancer diagnoses will be reported this year, and one out of six men will develop prostate tumors within their lives. Approximately 29,700 men are expected to die of the disease this year.

Tc-99m MIP-1404 (developed by Molecular Insight Pharmaceuticals Inc., a wholly owned subsidiary of Progenics Pharmaceuticals Inc.) is now in a phase II international multicenter study. Further studies and U.S. Food and Drug Administration approval are necessary before this radiopharmaceutical could be introduced to general clinical practice for prostate cancer imaging.


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
2. Molecular probes identify changes in fibronectin that may lead to disease
3. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
4. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
5. Scientists discover distinct molecular subtype of prostate cancer
6. New molecular structure offers first picture of a protein family vital to human health
7. Grb2 holds powerful molecular signaling pathway in check
8. Better treatment for brain cancer revealed by new molecular insights
9. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
10. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
11. Molecular switch identified that controls key cellular process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... TopConsumerReviews.com recently awarded their highest five-star ... promote pancreatic health and regulate blood sugar levels . , Preventing diabetes ... negative side effects, and with the changes in today’s healthcare industry, not everyone ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... you brush more effectively even on the go. Their electric toothbrushes aggressively attack ... gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology with a ...
(Date:9/22/2017)... ... September 22, 2017 , ... The freshly released ... doorstep. According to Smart Mart, customers can now order vegetable, fruit, snacks, dairy, ... customers can find clothing at discounted prices. Apart from this, Smart Mart has ...
(Date:9/21/2017)... Aliso Viejo, CA (PRWEB) , ... September 21, 2017 , ... ... never been so fun and easy to do. Users can select from up to ... more all with a click of a mouse all within Final Cut Pro ...
(Date:9/21/2017)... Chicago, IL (PRWEB) , ... September 21, 2017 , ... ... set to run from September 11 to the end of November. , The Chicago, ... out to their community and teach them about the ease of taking their personal ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
(Date:9/5/2017)... Sept. 5, 2017  Just 18 months after its ... pleased to announce the appointment of three new senior ... , Dominic Jones-Phillips and James Wright ... Tammy Wynne ... market access writers. She has over ten years, experience ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s ... must-read guide to the latest innovations happening across the ... industry publication to focus on providing a comprehensive look ... the issue covers the most innovative companies, startups, divisions, ... "Everyone in this industry ...
Breaking Medicine Technology: